MARKET

NVIV

NVIV

InVivo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6606
+0.0406
+6.55%
After Hours: 0.6500 -0.0106 -1.60% 18:09 05/14 EDT
OPEN
0.6400
PREV CLOSE
0.6200
HIGH
0.6699
LOW
0.6230
VOLUME
571.12K
TURNOVER
--
52 WEEK HIGH
2.550
52 WEEK LOW
0.4975
MARKET CAP
22.64M
P/E (TTM)
-0.1856
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 4d ago
10-Q: INVIVO THERAPEUTICS HOLDINGS CORP.
(EDGAR Online via COMTEX) -- Item 2.MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. The following management's...
Edgar Online - (EDG = 10Q, 10K) · 5d ago
UPDATE 1-InVivo signs deal to buy French agribusiness rival Soufflet
reuters.com · 05/03 13:21
Deals of the day-Mergers and acquisitions
reuters.com · 05/03 13:00
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer...
Business Wire · 03/12 13:00
Spero Therapeutics Announces Fourth Quarter and Full-Year 2020 Operating Results and Provides Business Update
CAMBRIDGE, Mar 11, 2021 (GLOBE NEWSWIRE via COMTEX) -- Tebipenem HBr advancing towards NDA submission in the second half of 2021 Conference call and live...
GlobeNewswire · 03/11 21:07
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer...
Business Wire · 03/05 13:00
10-K: INVIVO THERAPEUTICS HOLDINGS CORP.
(EDGAR Online via COMTEX) -- Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion should be...
Edgar Online - (EDG = 10Q, 10K) · 03/01 21:31
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVIV. Analyze the recent business situations of InVivo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS
Institutional Holdings
Institutions: 37
Institutional Holdings: 2.32M
% Owned: 6.76%
Shares Outstanding: 34.26M
TypeInstitutionsShares
Increased
6
1.58M
New
4
375.87K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+1.11%
Healthcare Equipment & Supplies
+1.17%
Key Executives
Non-Executive Chairman/Independent Director
Ann Merrifield
Non-Executive Chairman/Independent Director
C. Ann Merrifield
President/Chief Executive Officer/Director
Richard Toselli
Chief Financial Officer/Chief Accounting Officer
Jeff Modestino
Chief Financial Officer
Richard Christopher
Independent Director
Daniel Marshak
Independent Director
Christina Morrison
Independent Director
Richard Roberts
Independent Director
Robert Rosenthal
No Data
  • All
  • Financials
  • Insiders
More
About NVIV
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Webull offers kinds of Invivo Therapeutics Holdings Corp stock information, including NASDAQ:NVIV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVIV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVIV stock methods without spending real money on the virtual paper trading platform.